July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
One and two-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital
Author Affiliations & Notes
  • Katrin Fasler
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Farid Afshar
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Reena Chopra
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Karsten Ulrich Kortuem
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Nikolas Pontikos
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Siegfried K Wagner
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College, London, United Kingdom
  • Laxmi Raja
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Hasaneen Al Janabi
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Thushanthi Ramakrishnan
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • GABRIELLA CLAIRE PRESTON
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Konstantinos Balaskas
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    University of Manchester, Manchester, United Kingdom
  • Adnan Tufail
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Praveen Patel
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Pearse Keane
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Katrin Fasler, Schweizerischer Fonds zur Verhütung und Bekämpfung der Blindheit (F), Vogt Stipendium (F); Farid Afshar, None; Reena Chopra, None; Karsten Kortuem, Allergan (F), Bayer (F), Google Deepmind, big picture (C); Nikolas Pontikos, None; Siegfried Wagner, None; Laxmi Raja, None; Hasaneen Al Janabi, None; Thushanthi Ramakrishnan, None; GABRIELLA PRESTON, None; Konstantinos Balaskas, Bayer (R), Heidelberg (R), Novartis (C), Novartis (R) (R), Topcon (R); Adnan Tufail, Allergan (C), Bayer (C), Genentech (C), Heidelberg Engineering (C), Novartis (C), Novartis (F), Roche (C); Praveen Patel, Bayer (C), Genentech Inc (C), Heidelberg Inc (C), Merk Inc (C), Novartis (C), Roche UK (C), SalutarisMD (R), Thrombogenics NV (C), Thrombogenics NV (F), Topcon Inc (F); Pearse Keane, Allergan (R), Bayer (R), Google (C), Haag-Streit (R), Heidelberg Engineering (R), Novartis (R), Topcon (R), Zeiss (R)
  • Footnotes
    Support  Alfred-Vogt Stipendium 2017, Stipendium vom Schweizerischen Fonds zur Verhütung und Bekämpfung der Blindheit (Switzerland)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katrin Fasler, Farid Afshar, Reena Chopra, Karsten Ulrich Kortuem, Nikolas Pontikos, Siegfried K Wagner, Laxmi Raja, Hasaneen Al Janabi, Thushanthi Ramakrishnan, GABRIELLA CLAIRE PRESTON, Konstantinos Balaskas, Adnan Tufail, Praveen Patel, Pearse Keane; One and two-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital. Invest. Ophthalmol. Vis. Sci. 2018;59(9):826.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in the developed world. The management of neovascular AMD (nAMD) has been transformed by the emergence of intravitreal anti-VEGF therapy, most powerfully demonstrated by pivotal trials including ANCHOR, MARINA, and VIEW. However, such trials may not reflect a real-world case mix rendering the visual outcomes unrepresentative. Here, we report on the visual outcomes within the first 24 months following commencement of intravitreal therapy in a large tertiary single-centre ophthalmic hospital.

Methods : A retrospective cohort study of all patients undergoing intravitreal therapy for nAMD from 2007 to 2017 was carried out through an automated batch data export from the Moorfields Eye Hospital Electronic Medical Record system, OpenEyes. Patients were treated by aflibercept or ranibizumab, depending on the guidelines at first injection. All data was checked for consistency and completeness. Statistical analysis was carried out using SPSS version 23.

Results : A total of 6,882 eyes from 5,614 patients (61.4% female) were included. Mean (SD) age at first injection was 79 (±8.6) years. Two-thousand one-hundred and forty-seven patients (31.2%) were injected with ranibizumab, 2,516 (36.6%) with aflibercept and 2,219 (32.2%) switched between agents during the data collection period. Mean (SD) baseline visual acuity was 55.6 (±16) letters. Mean (SD) visual acuity at 12 months and 24 months was 62.18 (±17) and 62.8 (±16) letters respectively. A mean (SD) of 7.5 (±2) injections were given during the first year, and 12.5 (±4) injections were given over the 24 month period. Of the eyes included, 18.8% and 20.5 % had an improvement of >= 15 letters, 72.4% and 68.4% of eyes maintained a visual acuity within ±15 letters of the baseline, and 8.8% and 11.1% of eyes lost 15 or more letters, at 12 months and 24 months respectively.

Conclusions : As per the pivotal trials, the majority of patients maintained their vision upon commencement of treatment although visual acuity gains were more modest. This is probably due to several reasons influencing outcomes of nAMD treatment in real-life (e.g. therapeutic adherence or accessibility of care). Compared to UK patients of a multi-country real-life study (Holz et al., 2015), our cohort had similar outcomes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×